Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Malignant Melanoma

Free Subscription Articles published in Melanoma Res Retrieve available abstracts of 295 articles: HTML format Text format

Single Articles

August 2018
1. MONTAUDIE H, Picard A, Panaia-Ferrari P, Boukari F, et al
   Painful acute thyroiditis following a first cure of Ipilimumab plus Nivolumab for metastatic melanoma.
   Melanoma Res. 2018;28:368-369.
   PubMed     Text format    
   
   
   July 2018
2. HUTCHINSON PE, Halsall JA, Popovici S, Papadogeorgakis E, et al
   Compromised vitamin D receptor signalling in malignant melanoma is associated with tumour progression and mitogen-activated protein kinase activity.
   Melanoma Res. 2018 Jul 12. doi: 10.1097/CMR.0000000000000475.
   PubMed     Text format     Abstract available
   
   
   
3. FERRIS LK, Gerami P, Skelsey MK, Peck G, et al
   Real-world performance and utility of a noninvasive gene expression assay to evaluate melanoma risk in pigmented lesions.
   Melanoma Res. 2018 Jul 12. doi: 10.1097/CMR.0000000000000478.
   PubMed     Text format     Abstract available
   
   
   
4. LYTH J
   Conditional recurrence-free survival in patients with primary stage I-II cutaneous malignant melanoma - a population-based study.
   Melanoma Res. 2018 Jul 9. doi: 10.1097/CMR.0000000000000479.
   PubMed     Text format     Abstract available
   
   
   
5. LAMIAUX M, Scalbert C, Lepesant P, Desmedt E, et al
   Severe skin toxicity with organ damage under the combination of targeted therapy following immunotherapy in metastatic melanoma.
   Melanoma Res. 2018 Jul 6. doi: 10.1097/CMR.0000000000000472.
   PubMed     Text format     Abstract available
   
   
   
6. GORLOV I, Orlow I, Ringelberg C, Hernando E, et al
   Identification of gene expression levels in primary melanoma associated with clinically meaningful characteristics.
   Melanoma Res. 2018 Jul 2. doi: 10.1097/CMR.0000000000000473.
   PubMed     Text format     Abstract available
   
   
   
7. GOMEZ-LEON N, Pacheco-Barcia V, Ballesteros AI, Fraga J, et al
   Skeletal muscle and solitary bone metastases from malignant melanoma: multimodality imaging and oncological outcome.
   Melanoma Res. 2018 Jul 2. doi: 10.1097/CMR.0000000000000466.
   PubMed     Text format     Abstract available
   
   
   June 2018
8. URBONAS V, Smailyte G
   Combination of cytokine-directed and anti-programmed cell death protein 1 therapy - a new attractive option in melanoma treatment?
   Melanoma Res. 2018 Jun 29. doi: 10.1097/CMR.0000000000000470.
   PubMed     Text format     Abstract available
   
   
   
9. RAMBHIA PH, Honda K, Arbesman J
   Nivolumab induced inflammation of seborrheic keratoses: a novel cutaneous manifestation in a metastatic melanoma patient.
   Melanoma Res. 2018 Jun 29. doi: 10.1097/CMR.0000000000000477.
   PubMed     Text format     Abstract available
   
   
   
10. MENSHAWY A, Eltonob AA, Barkat SA, Ghanem A, et al
    Nivolumab monotherapy or in combination with ipilimumab for metastatic melanoma: systematic review and meta-analysis of randomized-controlled trials.
    Melanoma Res. 2018 Jun 27. doi: 10.1097/CMR.0000000000000467.
    PubMed     Text format     Abstract available
    
    
    
11. PUZA CJ, Barbas AS, Mosca PJ
    Outcomes of patients with a pretransplant history of early-stage melanoma.
    Melanoma Res. 2018 Jun 25. doi: 10.1097/CMR.0000000000000471.
    PubMed     Text format     Abstract available
    
    
    
12. MORGADO-CARRASCO D, Moreno-Rivera N, Fusta-Novell X, Garcia-Herrera A, et al
    Histiocytoid Sweet's syndrome during combined therapy with BRAF and MEK inhibitors for metastatic melanoma.
    Melanoma Res. 2018;28:256-257.
    PubMed     Text format    
    
    
    May 2018
13. HAFLIGER EM, Ramelyte E, Mangana J, Kunz M, et al
    Metastatic acral lentiginous melanoma in a tertiary referral center in Switzerland: a systematic analysis.
    Melanoma Res. 2018 May 29. doi: 10.1097/CMR.0000000000000465.
    PubMed     Text format     Abstract available
    
    
    
14. IACONO D, Cinausero M, Gerratana L, Angione V, et al
    Tumour-infiltrating lymphocytes, programmed death ligand 1 and cyclooxygenase-2 expression in skin melanoma of elderly patients: clinicopathological correlations.
    Melanoma Res. 2018 May 22. doi: 10.1097/CMR.0000000000000462.
    PubMed     Text format     Abstract available
    
    
    
15. BRUTTING J, Bergmann M, Garzarolli M, Rauschenberg R, et al
    Unmet information needs of patients with melanoma in Germany.
    Melanoma Res. 2018 May 21. doi: 10.1097/CMR.0000000000000464.
    PubMed     Text format     Abstract available
    
    
    
16. TETERYCZ P, Jagodzinska-Mucha P, Cybulska-Stopa B, Mariuk-Jarema A, et al
    High baseline neutrophil-to-lymphocyte ratio predicts worse outcome in patients with metastatic BRAF-positive melanoma treated with BRAF and MEK inhibitors.
    Melanoma Res. 2018 May 18. doi: 10.1097/CMR.0000000000000461.
    PubMed     Text format     Abstract available
    
    
    
17. FACINA AS, Facina G, Guerreiro da Silva IDC, Correa SAA, et al
    Pregnancy and the apoptotic pathway in experimental melanoma.
    Melanoma Res. 2018 May 17. doi: 10.1097/CMR.0000000000000452.
    PubMed     Text format     Abstract available
    
    
    
18. ZHOU X, Zeng Y, Jiang H, Xia L, et al
    Predictive value of excision repair cross-complementing group 2 gene Lys751Gln and Asp312Asn polymorphisms in melanoma risk.
    Melanoma Res. 2018 May 15. doi: 10.1097/CMR.0000000000000463.
    PubMed     Text format     Abstract available
    
    
    
19. TSOUTSOS D, Papadopoulos S, Kehagias G, Mara A, et al
    Epidemiological trends in the diagnosis of melanoma in a Southern European population: analysis of a large database from a tertiary referral center.
    Melanoma Res. 2018 May 14. doi: 10.1097/CMR.0000000000000456.
    PubMed     Text format     Abstract available
    
    
    
20. AFZAL MZ, Shirai K
    Immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy alone versus immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy in combination with anti-RANKL denosumuab in malignant melanoma: a retrospective analysis at a tertiary care center.
    Melanoma Res. 2018 May 10. doi: 10.1097/CMR.0000000000000459.
    PubMed     Text format     Abstract available
    
    
    
21. TENGDA L, Shuping L, Mingli G, Jie G, et al
    Serum exosomal microRNAs as potent circulating biomarkers for melanoma.
    Melanoma Res. 2018 May 10. doi: 10.1097/CMR.0000000000000450.
    PubMed     Text format     Abstract available
    
    
    
22. ASCIERTO PA, Bastholt L, Ferrucci PF, Hansson J, et al
    The impact of patient characteristics and disease-specific factors on first-line treatment decisions for BRAF-mutated melanoma: results from a European expert panel study.
    Melanoma Res. 2018 May 10. doi: 10.1097/CMR.0000000000000455.
    PubMed     Text format     Abstract available
    
    
    
23. MOSHE M, Levi A, Ad-El D, Ben-Amitai D, et al
    Malignant melanoma clinically mimicking pyogenic granuloma: comparison of clinical evaluation and histopathology.
    Melanoma Res. 2018 May 10. doi: 10.1097/CMR.0000000000000451.
    PubMed     Text format     Abstract available
    
    
    
24. SCHOUWENBURG MG, Jochems A, Leeneman B, Franken MG, et al
    Vemurafenib in BRAF-mutant metastatic melanoma patients in real-world clinical practice: prognostic factors associated with clinical outcomes.
    Melanoma Res. 2018 May 10. doi: 10.1097/CMR.0000000000000453.
    PubMed     Text format     Abstract available
    
    
    
25. GONG HZ, Zheng HY, Li J
    The clinical significance of KIT mutations in melanoma: a meta-analysis.
    Melanoma Res. 2018 May 9. doi: 10.1097/CMR.0000000000000454.
    PubMed     Text format     Abstract available
    
    
    April 2018
26. SEBESTYEN T, Mohos A, Liszkay G, Somlai B, et al
    Correlation with lymphocyte infiltration, but lack of prognostic significance of MECA-79-positive high endothelial venules in primary malignant melanoma.
    Melanoma Res. 2018 Apr 20. doi: 10.1097/CMR.0000000000000457.
    PubMed     Text format     Abstract available
    
    
    
27. LEE WJ, Lee YJ, Shin HJ, Won CH, et al
    Clinicopathological significance of tumor-infiltrating lymphocytes and programmed death-1 expression in cutaneous melanoma: a comparative study on clinical subtypes.
    Melanoma Res. 2018 Apr 9. doi: 10.1097/CMR.0000000000000449.
    PubMed     Text format     Abstract available
    
    
    
28. SIA DIT, Thaung C, O'Hanlon-Brown C, Cohen VML, et al
    Immune privilege: failure of immunotherapy in controlling metastatic cutaneous melanoma to the eye.
    Melanoma Res. 2018 Apr 9. doi: 10.1097/CMR.0000000000000443.
    PubMed     Text format     Abstract available
    
    
    
29. BASSOLI S, Pellegrini C, Longo C, Di Nardo L, et al
    Clinical, dermoscopic, and confocal features of nevi and melanomas in a multiple primary melanoma patient with the MITF p.E318K homozygous mutation.
    Melanoma Res. 2018;28:166-169.
    PubMed     Text format    
    
    
    
30. TAKAHASHI A, Tsutsumida A, Namikawa K, Yamazaki N, et al
    Fulminant type 1 diabetes associated with nivolumab in a patient with metastatic melanoma.
    Melanoma Res. 2018;28:159-160.
    PubMed     Text format    
    
    
    March 2018
31. TURNER KA, Manouchehri JM, Kalafatis M
    Sensitization of recombinant human tumor necrosis factor-related apoptosis-inducing ligand-resistant malignant melanomas by quercetin.
    Melanoma Res. 2018 Mar 28. doi: 10.1097/CMR.0000000000000447.
    PubMed     Text format     Abstract available
    
    
    
32. TERNOV NK, Lambine TL, Wagenblast ALH, Clasen-Linde E, et al
    Targeted ultrasound and fine-needle aspiration cytology for sentinel node diagnostics in early-stage melanoma: a validation study.
    Melanoma Res. 2018 Mar 27. doi: 10.1097/CMR.0000000000000448.
    PubMed     Text format     Abstract available
    
    
    
33. CHESNEY J, Imbert-Fernandez Y, Telang S, Baum M, et al
    Potential clinical and immunotherapeutic utility of talimogene laherparepvec for patients with melanoma after disease progression on immune checkpoint inhibitors and BRAF inhibitors.
    Melanoma Res. 2018 Mar 21. doi: 10.1097/CMR.0000000000000444.
    PubMed     Text format     Abstract available
    
    
    
34. KLEEMANN J, Hrgovic I, Ter-Nedden J, Kleimann P, et al
    Fatty acid receptor GPR120: a novel marker for human melanoma.
    Melanoma Res. 2018 Mar 21. doi: 10.1097/CMR.0000000000000445.
    PubMed     Text format     Abstract available
    
    
    
35. LADE-KELLER J, Yuusufi S, Riber-Hansen R, Steiniche T, et al
    Telomerase reverse transcriptase promoter mutations and solar elastosis in cutaneous melanoma.
    Melanoma Res. 2018 Mar 21. doi: 10.1097/CMR.0000000000000446.
    PubMed     Text format     Abstract available
    
    
    
36. NASARRE P, Bonilla IV, Metcalf JS, Hilliard EG, et al
    TRAF3-interacting protein 3, a new oncotarget, promotes tumor growth in melanoma.
    Melanoma Res. 2018 Mar 16. doi: 10.1097/CMR.0000000000000440.
    PubMed     Text format     Abstract available
    
    
    
37. GESKIN LJ, Damiano JJ, Patrone CC, Butterfield LH, et al
    Three antigen-loading methods in dendritic cell vaccines for metastatic melanoma.
    Melanoma Res. 2018 Mar 14. doi: 10.1097/CMR.0000000000000441.
    PubMed     Text format     Abstract available
    
    
    
38. DE UNAMUNO B, Garcia-Casado Z, Banuls J, Requena C, et al
    CDKN2A germline alterations in melanoma patients with personal or familial history of pancreatic cancer.
    Melanoma Res. 2018 Mar 14. doi: 10.1097/CMR.0000000000000442.
    PubMed     Text format     Abstract available
    
    
    
39. STOWMAN AM, Hickman AW, Mauldin IS, Mahmutovic A, et al
    Lymphoid aggregates in desmoplastic melanoma have features of tertiary lymphoid structures.
    Melanoma Res. 2018 Mar 13. doi: 10.1097/CMR.0000000000000439.
    PubMed     Text format     Abstract available
    
    
    
40. FOLEY KC, Nishimura MI, Moore TV
    Combination immunotherapies implementing adoptive T-cell transfer for advanced-stage melanoma.
    Melanoma Res. 2018 Mar 8. doi: 10.1097/CMR.0000000000000436.
    PubMed     Text format     Abstract available
    
    
    February 2018
41. MACHIRAJU D, Moll I, Gebhardt C, Sucker A, et al
    STAT5 expression correlates with recurrence and survival in melanoma patients treated with interferon-alpha.
    Melanoma Res. 2018 Feb 26. doi: 10.1097/CMR.0000000000000435.
    PubMed     Text format     Abstract available
    
    
    
42. DIMITRIOU F, Frauchiger AL, Urosevic-Maiwald M, Naegeli MC, et al
    Sarcoid-like reactions in patients receiving modern melanoma treatment.
    Melanoma Res. 2018 Feb 26. doi: 10.1097/CMR.0000000000000437.
    PubMed     Text format     Abstract available
    
    
    
43. GONZALEZ-CAO M, Mayo de Las Casas C, Jordana Ariza N, Manzano JL, et al
    Early evolution of BRAFV600 status in the blood of melanoma patients correlates with clinical outcome and identifies patients refractory to therapy.
    Melanoma Res. 2018 Feb 23. doi: 10.1097/CMR.0000000000000432.
    PubMed     Text format     Abstract available
    
    
    
44. TESTORI AA, Suciu S, van Akkooi ACJ, Suppa M, et al
    Lymph node ratio as a prognostic factor in melanoma: results from European Organization for Research and Treatment of Cancer 18871, 18952, and 18991 studies.
    Melanoma Res. 2018 Feb 9. doi: 10.1097/CMR.0000000000000433.
    PubMed     Text format     Abstract available
    
    
    
45. GANZETTI G, Sartini D, Campanati A, Rubini C, et al
    Nicotinamide N-methyltransferase: potential involvement in cutaneous malignant melanoma.
    Melanoma Res. 2018 Feb 7. doi: 10.1097/CMR.0000000000000430.
    PubMed     Text format     Abstract available
    
    
    
46. YANAGITA M, Luke JJ, Hodi FS, Janne PA, et al
    Isolation and characterization of circulating melanoma cells by size filtration and fluorescent in-situ hybridization.
    Melanoma Res. 2018 Feb 5. doi: 10.1097/CMR.0000000000000431.
    PubMed     Text format     Abstract available
    
    
    
47. KOTHAPALLI A, Khattak MA
    Safety and efficacy of anti-PD-1 therapy for metastatic melanoma and non-small-cell lung cancer in patients with viral hepatitis: a case series.
    Melanoma Res. 2018 Feb 5. doi: 10.1097/CMR.0000000000000434.
    PubMed     Text format     Abstract available
    
    
    January 2018
48. GEUKES FOPPEN MH, Boogerd W, Blank CU, van Thienen JV, et al
    Clinical and radiological response of BRAF inhibition and MEK inhibition in patients with brain metastases from BRAF-mutated melanoma.
    Melanoma Res. 2018 Jan 19. doi: 10.1097/CMR.0000000000000429.
    PubMed     Text format     Abstract available
    
    
    
49. NARDIN C, Mateus C, Texier M, Lanoy E, et al
    Tolerance and outcomes of stereotactic radiosurgery combined with anti-programmed cell death-1 (pembrolizumab) for melanoma brain metastases.
    Melanoma Res. 2018 Jan 19. doi: 10.1097/CMR.0000000000000413.
    PubMed     Text format     Abstract available
    
    
    
50. ROSE AM, Radia UK, Luo R, Kalirai H, et al
    Multiple primary malignancies and prolonged survival in a patient with widespread metastatic cutaneous melanoma.
    Melanoma Res. 2018 Jan 17. doi: 10.1097/CMR.0000000000000426.
    PubMed     Text format    
    
    
    
51. ZHU W, Li S, Zou B, Liu H, et al
    Expressions and clinical significance of HER4 and CD44 in sinonasal mucosal malignant melanoma.
    Melanoma Res. 2018 Jan 5. doi: 10.1097/CMR.0000000000000428.
    PubMed     Text format     Abstract available
    
    
    
52. DANISH H, Ferris MJ, Balagamwala E, Switchenko JM, et al
    Comparative outcomes and toxicities for ruthenium-106 versus palladium-103 in the treatment of choroidal melanoma.
    Melanoma Res. 2018 Jan 3. doi: 10.1097/CMR.0000000000000420.
    PubMed     Text format     Abstract available
    
    
    December 2017
53. DEL CARPIO HUERTA LP, Mas Castells M, Anguera Palacios G, Sullivan I, et al
    A novel KRAS mutation in metastasic conjunctival melanoma: a case report and literature review.
    Melanoma Res. 2017 Dec 20. doi: 10.1097/CMR.0000000000000423.
    PubMed     Text format     Abstract available
    
    
    
54. WEITMAN ES, Perez M, Thompson JF, Andtbacka RHI, et al
    Quality of life patient-reported outcomes for locally advanced cutaneous melanoma.
    Melanoma Res. 2017 Dec 19. doi: 10.1097/CMR.0000000000000425.
    PubMed     Text format     Abstract available
    
    
    
55. GALLO S, Coha V, Caravelli D, Becco P, et al
    BRAF-inhibitors can exert control of disease in BRAF T599I mutated melanoma: a case report.
    Melanoma Res. 2017 Dec 11. doi: 10.1097/CMR.0000000000000417.
    PubMed     Text format     Abstract available
    
    
    
56. BISSCHOP C, Ter Elst A, Bosman LJ, Platteel I, et al
    Rapid BRAF mutation tests in patients with advanced melanoma: comparison of immunohistochemistry, Droplet Digital PCR, and the Idylla Mutation Platform.
    Melanoma Res. 2017 Dec 11. doi: 10.1097/CMR.0000000000000421.
    PubMed     Text format     Abstract available
    
    
    
57. SEREMET T, Planken S, Schreuer M, Jansen Y, et al
    Illustrative cases for monitoring by quantitative analysis of BRAF/NRAS ctDNA mutations in liquid biopsies of metastatic melanoma patients who gained clinical benefits from anti-PD1 antibody therapy.
    Melanoma Res. 2017 Dec 8. doi: 10.1097/CMR.0000000000000415.
    PubMed     Text format     Abstract available
    
    
    
58. LOYSON T, Werbrouck E, Punie K, Bonne L, et al
    Hemorrhage of liver and bone metastases as a result of rapid response to dual BRAF/MEK inhibition in metastatic melanoma: a case report.
    Melanoma Res. 2017 Dec 5. doi: 10.1097/CMR.0000000000000419.
    PubMed     Text format     Abstract available
    
    
    
59. MENZIES S, Barry R, Ormond P
    Multiple primary melanoma: a single centre retrospective review.
    Melanoma Res. 2017;27:638-640.
    PubMed     Text format     Abstract available
    
    
    
60. SCHINZARI G, Rossi E, Cassano A, Dadduzio V, et al
    Cisplatin, dacarbazine and vinblastine as first line chemotherapy for liver metastatic uveal melanoma in the era of immunotherapy: a single institution phase II study.
    Melanoma Res. 2017;27:591-595.
    PubMed     Text format     Abstract available
    
    
    
61. HALLMEYER S, Gonzalez R, Lawson DH, Cranmer LD, et al
    Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E.
    Melanoma Res. 2017;27:585-590.
    PubMed     Text format     Abstract available
    
    
    
62. ROBINSON JP, Rebecca VW, Kircher DA, Silvis MR, et al
    Resistance mechanisms to genetic suppression of mutant NRAS in melanoma.
    Melanoma Res. 2017;27:545-557.
    PubMed     Text format     Abstract available
    
    
    
63. VAN DER WEYDEN L, Arends MJ, Brenn T, Tuting T, et al
    Widespread spontaneous hyperproliferation, melanosis and melanoma in Hgf-Cdk4R24C mice.
    Melanoma Res. 2017 Dec 1. doi: 10.1097/CMR.0000000000000414.
    PubMed     Text format    
    
    
    November 2017
64. BRANCA M, Orso S, Molinari RC, Xu H, et al
    Is nonmetastatic cutaneous melanoma predictable through genomic biomarkers?
    Melanoma Res. 2017 Nov 29. doi: 10.1097/CMR.0000000000000412.
    PubMed     Text format     Abstract available
    
    
    
65. CHESNEY J, Awasthi S, Curti B, Hutchins L, et al
    Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB-IVM1c melanoma.
    Melanoma Res. 2017 Nov 22. doi: 10.1097/CMR.0000000000000399.
    PubMed     Text format     Abstract available
    
    
    
66. HADDEN NJ, McIntosh JRD, Jay S, Whittaker PJ, et al
    Prognostic factors in patients with metastatic spinal cord compression secondary to melanoma: a systematic review.
    Melanoma Res. 2017 Nov 14. doi: 10.1097/CMR.0000000000000411.
    PubMed     Text format     Abstract available
    
    
    
67. KUO JC, Lilly LB, Hogg D
    Immune checkpoint inhibitor therapy in a liver transplant recipient with a rare subtype of melanoma: a case report and literature review.
    Melanoma Res. 2017 Nov 14. doi: 10.1097/CMR.0000000000000410.
    PubMed     Text format     Abstract available
    
    
    
68. BRZOZOWSKA M, Wierzba W, Sliwczynski A, Swierkowski M, et al
    Analysis of survival of patients treated with vemurafenib, ipilimumab and dabrafenib for advanced skin melanoma in daily clinical practice (Real-World Data): retrospective analysis of patients treated under drug/reimbursement programmes in Poland in 2
    Melanoma Res. 2017 Nov 8. doi: 10.1097/CMR.0000000000000408.
    PubMed     Text format     Abstract available
    
    
    October 2017
69. PACHMANN K, Willecke-Hochmuth R, Schneider K, Kaatz M, et al
    Circulating epithelial tumor cells as a prognostic tool for malignant melanoma.
    Melanoma Res. 2017 Oct 25. doi: 10.1097/CMR.0000000000000407.
    PubMed     Text format     Abstract available
    
    
    
70. TANG Y, Xie C, Zhang Y, Qin Y, et al
    Overexpression of mRNA-decapping enzyme 1a predicts disease-specific survival in malignant melanoma.
    Melanoma Res. 2017 Oct 25. doi: 10.1097/CMR.0000000000000406.
    PubMed     Text format     Abstract available
    
    
    
71. UPRETY D, Bista A, Chennamadhavuni A, Niroula A, et al
    Survival trends among patients with metastatic melanoma in the pretargeted and the post-targeted era: a US population-based study.
    Melanoma Res. 2017 Oct 11. doi: 10.1097/CMR.0000000000000394.
    PubMed     Text format     Abstract available
    
    
    
72. FAILING JJ, Yan Y, Porrata LF, Markovic SN, et al
    Lymphocyte-to-monocyte ratio is associated with survival in pembrolizumab-treated metastatic melanoma patients.
    Melanoma Res. 2017 Oct 9. doi: 10.1097/CMR.0000000000000404.
    PubMed     Text format     Abstract available
    
    
    
73. SHEN X, Fan Y, Cao S
    A review of primary malignant melanoma arising in an ovarian cystic teratoma.
    Melanoma Res. 2017 Oct 9. doi: 10.1097/CMR.0000000000000402.
    PubMed     Text format     Abstract available
    
    
    
74. ALESSI C, Scapulatempo Neto C, Viana CR, Vazquez VL, et al
    PD-1/PD-L1 and VEGF-A/VEGF-C expression in lymph node microenvironment and association with melanoma metastasis and survival.
    Melanoma Res. 2017 Oct 3. doi: 10.1097/CMR.0000000000000396.
    PubMed     Text format     Abstract available
    
    
    
75. TSIOGKA A, Jansky GL, Bauer JW, Koelblinger P, et al
    Fulminant type 1 diabetes after adjuvant ipilimumab therapy in cutaneous melanoma.
    Melanoma Res. 2017;27:524-525.
    PubMed     Text format    
    
    
    
76. ABOUDARAM A, Modesto A, Chaltiel L, Gomez-Roca C, et al
    Concurrent radiotherapy for patients with metastatic melanoma and receiving anti-programmed-death 1 therapy: a safe and effective combination.
    Melanoma Res. 2017;27:485-491.
    PubMed     Text format     Abstract available
    
    
    September 2017
77. MARTINEZ-GARCIA MA, Riveiro-Falkenbach E, Rodriguez-Peralto JL, Nagore E, et al
    A prospective multicenter cohort study of cutaneous melanoma: clinical staging and potential associations with HIF-1alpha and VEGF expressions.
    Melanoma Res. 2017 Sep 6. doi: 10.1097/CMR.0000000000000393.
    PubMed     Text format     Abstract available
    
    
    
78. DE SOUZA NETO FP, Bernardes SS, Marinello PC, Melo GP, et al
    Metformin: oxidative and proliferative parameters in-vitro and in-vivo models of murine melanoma.
    Melanoma Res. 2017 Sep 4. doi: 10.1097/CMR.0000000000000391.
    PubMed     Text format     Abstract available
    
    
    
79. YUKI A, Takenouchi T, Takatsuka S, Ishiguro T, et al
    A case of pure red cell aplasia during nivolumab therapy for cardiac metastatic melanoma.
    Melanoma Res. 2017 Sep 1. doi: 10.1097/CMR.0000000000000392.
    PubMed     Text format     Abstract available
    
    
    
80. TAHA T, Tzuk-Shina T, Forschner I, Bar-Sela G, et al
    Acute motor and sensory axonal neuropathy related to treatment with MEK inhibitors in a patient with advanced melanoma.
    Melanoma Res. 2017 Sep 1. doi: 10.1097/CMR.0000000000000390.
    PubMed     Text format     Abstract available
    
    
    August 2017
81. LI Y, Umbach DM, Li L
    Putative genomic characteristics of BRAF V600K versus V600E cutaneous melanoma.
    Melanoma Res. 2017 Aug 28. doi: 10.1097/CMR.0000000000000388.
    PubMed     Text format     Abstract available
    
    
    
82. TARHINI AA, Floros T, Lin HM, Lin Y, et al
    A unique gene expression signature is significantly differentially expressed in tumor-positive or tumor-negative sentinel lymph nodes in patients with melanoma.
    Melanoma Res. 2017 Aug 18. doi: 10.1097/CMR.0000000000000383.
    PubMed     Text format     Abstract available
    
    
    
83. GLITZA IC, Guha-Thakurta N, D'Souza NM, Amaria RN, et al
    Bevacizumab as an effective treatment for radiation necrosis after radiotherapy for melanoma brain metastases.
    Melanoma Res. 2017 Aug 16. doi: 10.1097/CMR.0000000000000389.
    PubMed     Text format     Abstract available
    
    
    
84. PURI A, Homsi J
    The safety of pembrolizumab in metastatic melanoma and rheumatoid arthritis.
    Melanoma Res. 2017 Aug 16. doi: 10.1097/CMR.0000000000000387.
    PubMed     Text format     Abstract available
    
    
    
85. BARBARIC J, Laversanne M, Znaor A
    Malignant melanoma incidence trends in a Mediterranean population following socioeconomic transition and war: results of age-period-cohort analysis in Croatia, 1989-2013.
    Melanoma Res. 2017 Aug 10. doi: 10.1097/CMR.0000000000000385.
    PubMed     Text format     Abstract available
    
    
    
86. GARDNER LJ, Ward M, Andtbacka RHI, Boucher KM, et al
    Risk factors for development of melanoma brain metastasis and disease progression: a single-center retrospective analysis.
    Melanoma Res. 2017 Aug 10. doi: 10.1097/CMR.0000000000000382.
    PubMed     Text format     Abstract available
    
    
    
87. ROGIERS A, Borght SV, Tuand K, Wolter P, et al
    Response to targeted therapy in two patients with metastatic melanoma carrying rare BRAF exon 15 mutations: A598_T599insV and V600_K601delinsE.
    Melanoma Res. 2017 Aug 10. doi: 10.1097/CMR.0000000000000376.
    PubMed     Text format     Abstract available
    
    
    
88. GOGAS HJ, Karalexi MA, Dessypris N, Antoniadis AG, et al
    The role of depression and personality traits in patients with melanoma: a South-European study.
    Melanoma Res. 2017 Aug 10. doi: 10.1097/CMR.0000000000000380.
    PubMed     Text format     Abstract available
    
    
    
89. GLADFELTER P, Darwish NHE, Mousa SA
    Current status and future direction in the management of malignant melanoma.
    Melanoma Res. 2017 Aug 10. doi: 10.1097/CMR.0000000000000379.
    PubMed     Text format     Abstract available
    
    
    
90. GRANGE F, Mohr P, Harries M, Ehness R, et al
    Economic burden of advanced melanoma in France, Germany and the UK: a retrospective observational study (Melanoma Burden-of-Illness Study).
    Melanoma Res. 2017 Aug 10. doi: 10.1097/CMR.0000000000000372.
    PubMed     Text format     Abstract available
    
    
    
91. STOWMAN AM, Hickman AW, Gru AA, Slingluff CL Jr, et al
    Histopathologic review of negative sentinel lymph node biopsies in thin melanomas: an argument for the routine use of immunohistochemistry.
    Melanoma Res. 2017;27:369-376.
    PubMed     Text format     Abstract available
    
    
    
92. DE ROSA F, Ridolfi L, Fiammenghi L, Petrini M, et al
    Dendritic cell vaccination for metastatic melanoma: a 14-year monoinstitutional experience.
    Melanoma Res. 2017;27:351-357.
    PubMed     Text format     Abstract available
    
    
    
93. SANGALLI A, Orlandi E, Poli A, Maurichi A, et al
    Sex-specific effect of RNASEL rs486907 and miR-146a rs2910164 polymorphisms' interaction as a susceptibility factor for melanoma skin cancer.
    Melanoma Res. 2017;27:309-314.
    PubMed     Text format     Abstract available
    
    
    July 2017
94. SOSSAU D, Kofler L, Eigentler T
    Type 1 diabetes mellitus caused by treatment with low-dose interferon-alpha in a melanoma patient.
    Melanoma Res. 2017 Jul 19. doi: 10.1097/CMR.0000000000000381.
    PubMed     Text format     Abstract available
    
    
    
95. BORGHI A, Corazza M, Virgili A, Lambertini AG, et al
    Impact of socioeconomic status and district of residence on cutaneous malignant melanoma prognosis: a survival study on incident cases between 1991 and 2011 in the province of Ferrara, northern Italy.
    Melanoma Res. 2017 Jul 18. doi: 10.1097/CMR.0000000000000378.
    PubMed     Text format     Abstract available
    
    
    
96. GRATZ V, Luttmann N, Haase O, Langan EA, et al
    Meningeal melanomatosis following discontinuation of dabrafenib: implications for the maintenance of long-term complete remission.
    Melanoma Res. 2017 Jul 18. doi: 10.1097/CMR.0000000000000373.
    PubMed     Text format     Abstract available
    
    
    
97. GAUCI ML, Laly P, Sarah LL, Behin A, et al
    Focal necrotizing myopathy with 'dropped-head syndrome' induced by cobimetinib in metastatic melanoma.
    Melanoma Res. 2017 Jul 7. doi: 10.1097/CMR.0000000000000377.
    PubMed     Text format     Abstract available
    
    
    June 2017
98. WANDLER A, Riber-Hansen R, Hager H, Hamilton-Dutoit SJ, et al
    Quantification of microRNA-21 and microRNA-125b in melanoma tissue.
    Melanoma Res. 2017 Jun 13. doi: 10.1097/CMR.0000000000000374.
    PubMed     Text format     Abstract available
    
    
    
99. TOMIZUKA T, Namikawa K, Higashi T
    Characteristics of melanoma in Japan: a nationwide registry analysis 2011-2013.
    Melanoma Res. 2017 Jun 12. doi: 10.1097/CMR.0000000000000375.
    PubMed     Text format     Abstract available
    
    
    
100. SOARES CD, Borges CF, Sena-Filho M, Almeida OP, et al
     Prognostic significance of cyclooxygenase 2 and phosphorylated Akt1 overexpression in primary nonmetastatic and metastatic cutaneous melanomas.
     Melanoma Res. 2017 Jun 9. doi: 10.1097/CMR.0000000000000368.
     PubMed     Text format     Abstract available
     
     
     
101. DAVICK JJ, Wick MR, Gru AA
     Development of a biclonal cutaneous T-cell lymphoproliferative process during treatment with immune checkpoint inhibitors for metastatic melanoma.
     Melanoma Res. 2017 Jun 1. doi: 10.1097/CMR.0000000000000371.
     PubMed     Text format     Abstract available
     
     
     
102. GIUDICE G, Robusto F, Vestita M, Annoscia P, et al
     Single-stage excision and sentinel lymph node biopsy in cutaneous melanoma in selected patients: a retrospective case-control study.
     Melanoma Res. 2017 Jun 1. doi: 10.1097/CMR.0000000000000370.
     PubMed     Text format     Abstract available
     
     
     
103. WANG Y, Wen XZ, Ba HJ, Li DD, et al
     A prognostic model for resectable acral melanoma patients on the basis of preoperative inflammatory markers.
     Melanoma Res. 2017 Jun 1. doi: 10.1097/CMR.0000000000000365.
     PubMed     Text format     Abstract available
     
     
     
104. MIRZA S, Hill E, Ludlow SP, Nanjappa S, et al
     Checkpoint inhibitor-associated drug reaction with eosinophilia and systemic symptom syndrome.
     Melanoma Res. 2017;27:271-273.
     PubMed     Text format     Abstract available
     
     
     
105. HAUEIS SA, Kranzlin P, Mangana J, Cheng PF, et al
     Does the distribution pattern of brain metastases during BRAF inhibitor therapy reflect phenotype switching?
     Melanoma Res. 2017;27:231-237.
     PubMed     Text format     Abstract available
     
     
     May 2017
106. FURDOVA A, Sramka M, Chorvath M, Kralik G, et al
     Clinical experience of stereotactic radiosurgery at a linear accelerator for intraocular melanoma.
     Melanoma Res. 2017 May 17. doi: 10.1097/CMR.0000000000000364.
     PubMed     Text format     Abstract available
     
     
     
107. MANGANA J, Cheng PF, Kaufmann C, Amann VC, et al
     Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland.
     Melanoma Res. 2017 May 15. doi: 10.1097/CMR.0000000000000359.
     PubMed     Text format     Abstract available
     
     
     
108. GUADAGNI S, Fiorentini G, Clementi M, Palumbo G, et al
     MGMT methylation correlates with melphalan pelvic perfusion survival in stage III melanoma patients: a pilot study.
     Melanoma Res. 2017 May 10. doi: 10.1097/CMR.0000000000000367.
     PubMed     Text format     Abstract available
     
     
     
109. LAKHTER AJ, Naidu SR
     Cyclic AMP-Epac signaling pathway contributes to repression of PUMA transcription in melanoma cells.
     Melanoma Res. 2017 May 4. doi: 10.1097/CMR.0000000000000363.
     PubMed     Text format     Abstract available
     
     
     
110. HOLTKAMP LHJ, Read RL, Emmett L, Thompson JF, et al
     Futility of imaging to stage melanoma patients with a positive sentinel lymph node.
     Melanoma Res. 2017 May 4. doi: 10.1097/CMR.0000000000000362.
     PubMed     Text format     Abstract available
     
     
     
111. STABLER S, Becquart C, Dumezy F, Terriou L, et al
     Hemophagocytic lymphohistiocytosis in patients with metastatic malignant melanoma.
     Melanoma Res. 2017 May 3. doi: 10.1097/CMR.0000000000000354.
     PubMed     Text format     Abstract available
     
     
     April 2017
112. MENDT M, Cardier JE
     Activation of the CXCR4 chemokine receptor enhances biological functions associated with B16 melanoma liver metastasis.
     Melanoma Res. 2017 Apr 25. doi: 10.1097/CMR.0000000000000346.
     PubMed     Text format     Abstract available
     
     
     
113. KYRGIDIS A, Lallas A, Moscarella E, Longo C, et al
     Does pregnancy influence melanoma prognosis? A meta-analysis.
     Melanoma Res. 2017 Apr 20. doi: 10.1097/CMR.0000000000000334.
     PubMed     Text format     Abstract available
     
     
     
114. DIAMANTOPOULOS PT, Gaggadi M, Kassi E, Benopoulou O, et al
     Late-onset nivolumab-mediated pneumonitis in a patient with melanoma and multiple immune-related adverse events.
     Melanoma Res. 2017 Apr 17. doi: 10.1097/CMR.0000000000000355.
     PubMed     Text format     Abstract available
     
     
     
115. PISCIOLI F, Pusiol T, Roncati L
     Critical points of T1 stage in primary melanoma.
     Melanoma Res. 2017 Apr 13. doi: 10.1097/CMR.0000000000000357.
     PubMed     Text format    
     
     
     
116. MURER C, Kranzlin-Stieger P, French LE, Dummer R, et al
     Successful treatment with imatinib after nilotinib and ipilimumab in a c-kit-mutated advanced melanoma patient: a case report.
     Melanoma Res. 2017 Apr 13. doi: 10.1097/CMR.0000000000000358.
     PubMed     Text format     Abstract available
     
     
     
117. TARHINI AA, Moschos SJ, Lin Y, Lin HM, et al
     Safety and efficacy of the antiganglioside GD3 antibody ecromeximab (KW2871) combined with high-dose interferon-alpha2b in patients with metastatic melanoma.
     Melanoma Res. 2017 Apr 7. doi: 10.1097/CMR.0000000000000353.
     PubMed     Text format     Abstract available
     
     
     
118. THOMSON CH, Cassell O, Peach H, Holloway S, et al
     Neuropathic pain and quality of life after wide local excision and sentinel lymph node biopsy for melanoma: a multicentre study.
     Melanoma Res. 2017;27:121-125.
     PubMed     Text format     Abstract available
     
     
     
119. ROGIERS A, Wolter P, Bechter O
     Dabrafenib plus trametinib rechallenge in four melanoma patients who previously progressed on this combination.
     Melanoma Res. 2017;27:164-167.
     PubMed     Text format     Abstract available
     
     
     
120. BLACKMON JT, Dhawan R, Terry NL, Conry RM, et al
     Response of BRAF inhibitor-associated squamous cell lung carcinoma to drug withdrawal.
     Melanoma Res. 2017;27:159-163.
     PubMed     Text format     Abstract available
     
     
     
121. AMODE R, Baroudjian B, Kowal A, Jebali M, et al
     Anti-programmed cell death protein 1 tolerance and efficacy after ipilimumab immunotherapy: observational study of 39 patients.
     Melanoma Res. 2017;27:110-115.
     PubMed     Text format     Abstract available
     
     
     March 2017
122. DE GIORGI V, Grazzini M, Benemei S, Marchionni N, et al
     beta-Blocker use and reduced disease progression in patients with thick melanoma: 8 years of follow-up.
     Melanoma Res. 2017 Mar 24. doi: 10.1097/CMR.0000000000000317.
     PubMed     Text format     Abstract available
     
     
     
123. HINTZSCHE JD, Gorden NT, Amato CM, Kim J, et al
     Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma.
     Melanoma Res. 2017 Mar 14. doi: 10.1097/CMR.0000000000000345.
     PubMed     Text format     Abstract available
     
     
     
124. LEON-FERRE RA, Kottschade LA, Block MS, McWilliams RR, et al
     Association between the use of surveillance PET/CT and the detection of potentially salvageable occult recurrences among patients with resected high-risk melanoma.
     Melanoma Res. 2017 Mar 14. doi: 10.1097/CMR.0000000000000344.
     PubMed     Text format     Abstract available
     
     
     
125. CARRERA C, Gual A, Diaz A, Puig-Butille JA, et al
     Prognostic role of the histological subtype of melanoma on the hands and feet in Caucasians.
     Melanoma Res. 2017 Mar 14. doi: 10.1097/CMR.0000000000000340.
     PubMed     Text format     Abstract available
     
     
     
126. FALLENI M, Savi F, Tosi D, Agape E, et al
     M1 and M2 macrophages' clinicopathological significance in cutaneous melanoma.
     Melanoma Res. 2017 Mar 7. doi: 10.1097/CMR.0000000000000352.
     PubMed     Text format     Abstract available
     
     
     
127. FUKUDA K, Funakoshi T, Sakurai T, Nakamura Y, et al
     Peptide-pulsed dendritic cell vaccine in combination with carboplatin and paclitaxel chemotherapy for stage IV melanoma.
     Melanoma Res. 2017 Mar 3. doi: 10.1097/CMR.0000000000000342.
     PubMed     Text format     Abstract available
     
     
     
128. BLASIG H, Bender C, Hassel JC, Eigentler TK, et al
     Reinduction of PD1-inhibitor therapy: first experience in eight patients with metastatic melanoma.
     Melanoma Res. 2017 Mar 2. doi: 10.1097/CMR.0000000000000341.
     PubMed     Text format     Abstract available
     
     
     
129. DE GIORGI V, Gori A, Savarese I, D'Errico A, et al
     Clinical and dermoscopic features of truly amelanotic plantar melanoma.
     Melanoma Res. 2017 Mar 1. doi: 10.1097/CMR.0000000000000337.
     PubMed     Text format     Abstract available
     
     
     
130. LOQUAI C, Schmidtmann I, Garzarolli M, Kaatz M, et al
     Interactions from complementary and alternative medicine in patients with melanoma.
     Melanoma Res. 2017 Mar 1. doi: 10.1097/CMR.0000000000000339.
     PubMed     Text format     Abstract available
     
     
     February 2017
131. DESVIGNES C, Abirached H, Templier C, Drumez E, et al
     BRAF inhibitor discontinuation and rechallenge in advanced melanoma patients with a complete initial treatment response.
     Melanoma Res. 2017 Feb 24. doi: 10.1097/CMR.0000000000000350.
     PubMed     Text format     Abstract available
     
     
     
132. TAS F, Erturk K
     Scalp melanoma is associated with high mitotic rate and is a poor prognostic factor for recurrence and outcome.
     Melanoma Res. 2017 Feb 23. doi: 10.1097/CMR.0000000000000351.
     PubMed     Text format     Abstract available
     
     
     
133. VIZKELETI L, Kiss T, Koroknai V, Ecsedi S, et al
     Altered integrin expression patterns shown by microarray in human cutaneous melanoma.
     Melanoma Res. 2017 Feb 23. doi: 10.1097/CMR.0000000000000322.
     PubMed     Text format     Abstract available
     
     
     
134. ITCHINS M, Ascierto PA, Menzies AM, Oatley M, et al
     A multireferral centre retrospective cohort analysis on the experience in treatment of metastatic uveal melanoma and utilization of sequential liver-directed treatment and immunotherapy.
     Melanoma Res. 2017 Feb 22. doi: 10.1097/CMR.0000000000000343.
     PubMed     Text format     Abstract available
     
     
     
135. MADU MF, Timmerman P, Wouters MW, van der Hiel B, et al
     PET/CT surveillance detects asymptomatic recurrences in stage IIIB and IIIC melanoma patients: a prospective cohort study.
     Melanoma Res. 2017 Feb 20. doi: 10.1097/CMR.0000000000000347.
     PubMed     Text format     Abstract available
     
     
     
136. LI FJ, Li LM, Zhang RH, Xu C, et al
     The role of 5-hydroxymethylcytosine in melanoma.
     Melanoma Res. 2017 Feb 20. doi: 10.1097/CMR.0000000000000349.
     PubMed     Text format     Abstract available
     
     
     
137. TESIO V, Ribero S, Castelli L, Bassino S, et al
     Psychological characteristics of early-stage melanoma patients: a cross-sectional study on 204 patients.
     Melanoma Res. 2017 Feb 15. doi: 10.1097/CMR.0000000000000348.
     PubMed     Text format     Abstract available
     
     
     
138. RIBERO S, Longo C, Specchio F, Piana S, et al
     Lymph nodes' capsular naevi are associated with high naevus count in melanoma patients: a case-control study.
     Melanoma Res. 2017 Feb 1. doi: 10.1097/CMR.0000000000000328.
     PubMed     Text format     Abstract available
     
     
     January 2017
139. PELLEGRINI C, Maturo MG, Martorelli C, Suppa M, et al
     Characterization of melanoma susceptibility genes in high-risk patients from Central Italy.
     Melanoma Res. 2017 Jan 31. doi: 10.1097/CMR.0000000000000323.
     PubMed     Text format     Abstract available
     
     
     
140. LINO-SILVA LS, Salcedo-Hernandez RA, Garcia-Perez L, Meneses-Garcia A, et al
     Basal neutrophil-to-lymphocyte ratio is associated with overall survival in melanoma.
     Melanoma Res. 2017 Jan 25. doi: 10.1097/CMR.0000000000000333.
     PubMed     Text format     Abstract available
     
     
     
141. GRAY A, Grushchak S, Mudaliar K, Kliethermes S, et al
     The microenvironment in primary cutaneous melanoma with associated spontaneous tumor regression: evaluation for T-regulatory cells and the presence of an immunosuppressive microenvironment.
     Melanoma Res. 2017 Jan 25. doi: 10.1097/CMR.0000000000000331.
     PubMed     Text format     Abstract available
     
     
     
142. OBEID JM, Hu Y, Erdag G, Leick KM, et al
     The heterogeneity of tumor-infiltrating CD8+ T cells in metastatic melanoma distorts their quantification: how to manage heterogeneity?
     Melanoma Res. 2017 Jan 21. doi: 10.1097/CMR.0000000000000330.
     PubMed     Text format     Abstract available
     
     
     
143. OBA J, Esmaeli B, Ellerhorst JA, Lyons GR, et al
     Trends in hepatocyte growth factor, insulin-like growth factor 1, thyroid-stimulating hormone, and leptin expression levels in uveal melanoma patient serum and tumor tissues: correlation to disease progression.
     Melanoma Res. 2017 Jan 21. doi: 10.1097/CMR.0000000000000329.
     PubMed     Text format     Abstract available
     
     
     
144. LADWA R, Atkinson V
     The cessation of anti-PD-1 antibodies of complete responders in metastatic melanoma.
     Melanoma Res. 2017 Jan 17. doi: 10.1097/CMR.0000000000000336.
     PubMed     Text format     Abstract available
     
     
     
145. TAS F, Erturk K
     Recurrence behavior in early-stage cutaneous melanoma: pattern, timing, survival, and influencing factors.
     Melanoma Res. 2017 Jan 17. doi: 10.1097/CMR.0000000000000332.
     PubMed     Text format     Abstract available
     
     
     
146. DE HAAN J, Lok CA, de Groot CJ, Crijns MB, et al
     Melanoma during pregnancy: a report of 60 pregnancies complicated by melanoma.
     Melanoma Res. 2017 Jan 17. doi: 10.1097/CMR.0000000000000327.
     PubMed     Text format     Abstract available
     
     
     
147. LV C, Dai H, Sun M, Zhao H, et al
     Mesenchymal stem cells induce epithelial mesenchymal transition in melanoma by paracrine secretion of transforming growth factor-beta.
     Melanoma Res. 2017 Jan 5. doi: 10.1097/CMR.0000000000000325.
     PubMed     Text format     Abstract available
     
     
     
148. BORRONI RG, Manganoni AM, Grassi S, Grasso M, et al
     Genetic counselling and high-penetrance susceptibility gene analysis reveal the novel CDKN2A p.D84V (c.251A>T) mutation in melanoma-prone families from Italy.
     Melanoma Res. 2017 Jan 4. doi: 10.1097/CMR.0000000000000324.
     PubMed     Text format     Abstract available
     
     
     December 2016
149. LINO-SILVA LS, Castillo-Medina AL, Salcedo-Hernandez RA, Garcia-Perez L, et al
     Exhaustive pathologic work-up in sentinel lymph node biopsy for melanoma: is it necessary?
     Melanoma Res. 2016 Dec 27. doi: 10.1097/CMR.0000000000000319.
     PubMed     Text format     Abstract available
     
     
     
150. MICEVIC G, Theodosakis N, Taube JM, Bosenberg MW, et al
     Attenuation of genome-wide 5-methylcytosine level is an epigenetic feature of cutaneous malignant melanomas.
     Melanoma Res. 2016 Dec 16. doi: 10.1097/CMR.0000000000000315.
     PubMed     Text format     Abstract available
     
     
     
151. BEHLING J, Kaes J, Munzel T, Grabbe S, et al
     New-onset third-degree atrioventricular block because of autoimmune-induced myositis under treatment with anti-programmed cell death-1 (nivolumab) for metastatic melanoma.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
152. MININI R, Rohrmann S, Braun R, Korol D, et al
     Incidence trends and clinical-pathological characteristics of invasive cutaneous melanoma from 1980 to 2010 in the canton of Zurich, Switzerland.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
153. PISCIOLI F, Pusiol T, Roncati L
     Thin melanoma subtyping fits well with the American Joint Committee on Cancer staging system.
     Melanoma Res. 2016;26:636.
     PubMed     Text format    
     
     
     
154. PISCIOLI F, Pusiol T, Roncati L
     Histopathological determination of thin melanomas at risk for metastasis.
     Melanoma Res. 2016;26:635.
     PubMed     Text format    
     
     
     November 2016
155. LEONTOVICH AA, Dronca RS, Nevala WK, Thompson MA, et al
     Effect of the lymphocyte-to-monocyte ratio on the clinical outcome of chemotherapy administration in advanced melanoma patients.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     October 2016
156. PAOLINO G, Panetta C, Cota C, Didona D, et al
     Vitamin D receptor immunohistochemistry variability in sun-exposed and non-sun-exposed melanomas.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
157. SHOUSHTARI AN, Bluth MJ, Goldman DA, Bitas C, et al
     Clinical features and response to systemic therapy in a historical cohort of advanced or unresectable mucosal melanoma.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
158. NGUYEN BH, Kuo J, Budiman A, Christie H, et al
     Two cases of clinical myasthenia gravis associated with pembrolizumab use in responding melanoma patients.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
159. VARTANIAN A, Baryshnikova M, Burova O, Afanasyeva D, et al
     Inhibitor of vasculogenic mimicry restores sensitivity of resistant melanoma cells to DNA-damaging agents.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
160. CHAKRAVARTI N, Ivan D, Trinh VA, Glitza IC, et al
     High cytotoxic T-lymphocyte-associated antigen 4 and phospho-Akt expression in tumor samples predicts poor clinical outcomes in ipilimumab-treated melanoma patients.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
161. LIM MS, Wang JH, Power DG, Redmond HP, et al
     Inflammatory regulation of stem-like cells in melanoma.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
162. ADAMS G, Foote M, Brown S, Burmeister B, et al
     Adjuvant external beam radiotherapy after therapeutic groin lymphadenectomy for patients with melanoma: a dosimetric comparison of three-dimensional conformal and intensity-modulated radiotherapy techniques.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
163. BOTTLAENDER L, Perier-Muzet M, Lapras V, Thomas L, et al
     Tumor-free osteosclerotic lesions in patients treated for metastatic melanoma using BRAF inhibitors.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
164. AMBER KT, Panganiban CM, Korta D, Feraudy S, et al
     A case report of bullous pemphigoid associated with a melanoma and review of the literature.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
165. MATHESON JA, Te Marvelde L, Mailer S, Speakman D, et al
     Prospective evaluation of prognostic indicators for early recurrence of cutaneous melanoma.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
166. HOAG JR, Hegde U, Zweifler R, Berwick M, et al
     Competing risks survival of older patients with metastatic cutaneous melanoma: a SEER population-based study.
     Melanoma Res. 2016;26:505-512.
     PubMed     Text format     Abstract available
     
     
     September 2016
167. KUBECEK O, Kopecky J
     Microsatellite instability in melanoma: a comprehensive review.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
168. MIRJACIC MARTINOVIC KM, Babovic NL, Dzodic RR, Jurisic VB, et al
     Beneficial in-vitro effects of interleukin-2, interleukin-12, and their combination on functional and receptor characteristics of natural killer cells in metastatic melanoma patients with normal serum lactate dehydrogenase levels.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
169. FAILING JJ, Finnes HD, Kottschade LA, Allred JB, et al
     Effects of commonly used chronic medications on the outcomes of ipilimumab therapy in patients with metastatic melanoma.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
170. KARABULUT YY, Erdogan S, Sayar H, Ergen A, et al
     Primary malignant melanoma of the urinary bladder: clinical, morphological, and molecular analysis of five cases.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
171. ROMAINE ST, Wells-Jordan P, de Haro T, Dave-Thakrar A, et al
     A small multimarker panel using simple immunohistochemistry methods is an adjunct to stage for cutaneous melanoma prognosis.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     August 2016
172. DANISH HH, Patel KR, Switchenko JM, Gillespie TW, et al
     The influence of postoperative lymph node radiation therapy on overall survival of patients with stage III melanoma, a National Cancer Database analysis.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
173. ZOROQUIAIN P, Mayo-Goldberg E, Alghamdi S, Alhumaid S, et al
     Melanocytoma-like melanoma may be the missing link between benign and malignant uveal melanocytic lesions in humans and dogs: a comparative study.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
174. MCQUADE JL, Posada LP, Lecagoonporn S, Cain S, et al
     A phase I study of TPI 287 in combination with temozolomide for patients with metastatic melanoma.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
175. FORTES C, Mastroeni S, Botta G, Boffetta P, et al
     Glutathione S-transferase M1 null genotype, household pesticides exposure and cutaneous melanoma.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
176. SADHU SS, Wang S, Averineni RK, Seefeldt T, et al
     In-vitro and in-vivo inhibition of melanoma growth and metastasis by the drug combination of celecoxib and dacarbazine.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
177. DETRIXHE A, Libon F, Mansuy M, Nikkels-Tassoudji N, et al
     Melanoma masquerading as nonmelanocytic lesions.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
178. DE LEEDE EM, Burgmans MC, Kapiteijn E, Luyten GP, et al
     Isolated (hypoxic) hepatic perfusion with high-dose chemotherapy in patients with unresectable liver metastases of uveal melanoma: results from two experienced centres.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
179. BRUNET-POSSENTI F, Mignot S, Deschamps L, Descamps V, et al
     Antiepidermis autoantibodies induced by anti-PD-1 therapy in metastatic melanoma.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     July 2016
180. DILLER ML, Kudchadkar RR, Delman KA, Lawson DH, et al
     Complete response to high-dose IL-2 and enhanced IFNgamma+Th17 : TREG ratio in a melanoma patient.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
181. ENNINGA EA, Nevala WK, Holtan SG, Leontovich AA, et al
     Galectin-9 modulates immunity by promoting Th2/M2 differentiation and impacts survival in patients with metastatic melanoma.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
182. FRANK GA, Aleksakhina SN, Zavalishina LE, Kekeyeva TV, et al
     BRAF and NRAS mutations in Russian melanoma patients: results of a nationwide study.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
183. KUZBICKI L, Lange D, Stanek-Widera A, Chwirot BW, et al
     Intratumoral expression of cyclooxygenase-2 (COX-2) is a negative prognostic marker for patients with cutaneous melanoma.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
184. OLSEN CM, Hyrich KL, Knight LL, Green AC, et al
     Melanoma risk in patients with rheumatoid arthritis treated with tumour necrosis factor alpha inhibitors: a systematic review and meta-analysis.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
185. MAYER JE, Swetter SM, Miller DR, Sober AJ, et al
     Association of nevus count with prevention attitudes and behaviors before melanoma diagnosis.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
186. TAS F, Erturk K
     Presence of histological regression as a prognostic factor in cutaneous melanoma patients.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     June 2016
187. FEDORENKO IV, Evernden B, Kenchappa RS, Sahebjam S, et al
     A rare case of leptomeningeal carcinomatosis in a patient with uveal melanoma: case report and review of literature.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
188. HERMS F, Kramkimel N, Regnier-Rosencher E, Carlotti A, et al
     Age and clear eyes are associated with an increased risk of cutaneous squamous cell carcinomas in vemurafenib-treated melanoma patients.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
189. WEN X, Wang Y, Ding Y, Li D, et al
     Safety of immune checkpoint inhibitors in Chinese patients with melanoma.
     Melanoma Res. 2016;26:284-9.
     PubMed     Text format     Abstract available
     
     
     
190. MEHTA A, Gupta A, Hannallah F, Koshy T, et al
     Myocarditis as an immune-related adverse event with ipilimumab/nivolumab combination therapy for metastatic melanoma.
     Melanoma Res. 2016;26:319-20.
     PubMed     Text format    
     
     
     May 2016
191. LUTTMANN N, Gratz V, Haase O, Eckey T, et al
     Rapid remission of symptomatic brain metastases in melanoma by programmed-death-receptor-1 inhibition.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
192. YANG S, Leone D, Frydenlund N, Hoang M, et al
     Frequency of telomerase reverse transcripter promoter mutations in desmoplastic melanoma subtypes: analyses of 76 cases.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
193. VAN DER PLOEG IM, Madu MF, van der Hage JA, Wouters MW, et al
     Blue dye can be safely omitted in most sentinel node procedures for melanoma.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
194. KUK SK, Won CH, Lee WJ, Shin WJ, et al
     Prognostic significance of nestin in primary malignant melanoma of the oral cavity.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
195. HUGEL R, Muendlein A, Volbeding L, Drexel H, et al
     Serum levels of hepatocyte growth factor as a potential tumor marker in patients with malignant melanoma.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
196. ROGERS Z, Elliott F, Kasparian NA, Bishop DT, et al
     Psychosocial, clinical and demographic features related to worry in patients with melanoma.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
197. ESCOBAR GF, Arraes JA, Bakos L, Ashton-Prolla P, et al
     Polymorphisms in CYP19A1 and NFKB1 genes are associated with cutaneous melanoma risk in southern Brazilian patients.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
198. LEE SF, Atkinson V
     A case of acute paraneoplastic neurological syndrome in BRAF mutant metastatic melanoma.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     April 2016
199. KROGH M, Christensen I, Bouwhuis M, Johansen JS, et al
     Prognostic and predictive value of YKL-40 in stage IIB-III melanoma.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
200. ROMMENS K, Jegou D, De Backer H, Weyler J, et al
     Seasonal variation in cutaneous melanoma incidence, link with recent UV levels: a population-based study in Belgium (2006-2011).
     Melanoma Res. 2016;26:195-201.
     PubMed     Text format     Abstract available
     
     
     
201. NGUYEN J, Bernert R, In K, Kang P, et al
     Gamma-interferon-inducible lysosomal thiol reductase is upregulated in human melanoma.
     Melanoma Res. 2016;26:125-37.
     PubMed     Text format     Abstract available
     
     
     
202. PAOLINO G, Moliterni E, Lopez T, Cardone M, et al
     Serum tryptase levels in melanoma patients: first results of clinicopathological features.
     Melanoma Res. 2016;26:207-8.
     PubMed     Text format    
     
     
     
203. VULTUR A, Schanstra T, Herlyn M
     The promise of 3D skin and melanoma cell bioprinting.
     Melanoma Res. 2016;26:205-6.
     PubMed     Text format    
     
     
     
204. CHENG C, Yang HW, Shang JF, Li WW, et al
     Identification of a small molecule that downregulates MITF expression and mediates antimelanoma activity in vitro.
     Melanoma Res. 2016;26:117-24.
     PubMed     Text format     Abstract available
     
     
     
205. WANG LE, Li C, Xiong P, Gershenwald JE, et al
     4-nitroquinoline-1-oxide-induced mutagen sensitivity and risk of cutaneous melanoma: a case-control analysis.
     Melanoma Res. 2016;26:181-7.
     PubMed     Text format     Abstract available
     
     
     March 2016
206. SKINNER CC, McMichael EL, Jaime-Ramirez AC, Abrams ZB, et al
     Folate-conjugated immunoglobulin targets melanoma tumor cells for NK cell effector functions.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
207. HWANG SJ, Carlos G, Wakade D, Sharma R, et al
     Ipilimumab-induced acute generalized exanthematous pustulosis in a patient with metastatic melanoma.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
208. JOSEPH RW, Cappel M, Tzou K, Bagaria S, et al
     Treatment of in-transit and metastatic melanoma in two patients treated with ipilimumab and topical imiquimod.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
209. PADDOCK LE, Lu SE, Bandera EV, Rhoads GG, et al
     Skin self-examination and long-term melanoma survival.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
210. BAROUDJIAN B, Lourenco N, Pages C, Chami I, et al
     Anti-PD1-induced collagenous colitis in a melanoma patient.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
211. QASSEMYAR A, Gabert PE, Kluza J, Duquennoy-Martinot V, et al
     Patient-derived tumor xenograft strategies for informed management of patients with metastatic melanoma.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
212. FLOUDAS CS, Chandra AB, Xu Y
     Vemurafenib in leptomeningeal carcinomatosis from melanoma: a case report of near-complete response and prolonged survival.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
213. LIN RL, Wang TJ, Joyce CJ, Mihm MC Jr, et al
     Decreased tumor-infiltrating lymphocytes in nodular melanomas compared with matched superficial spreading melanomas.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
214. WHIPPLE CA, Boni A, Fisher JL, Hampton TH, et al
     The mitogen-activated protein kinase pathway plays a critical role in regulating immunological properties of BRAF mutant cutaneous melanoma cells.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
215. JIANG H, Xu W, Zhang F, Wei L, et al
     Quantitative assessment of the association between XRCC1 Arg399Gln and Arg194Trp polymorphisms and risk of cutaneous melanoma.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
216. ESPINOSA E, Soriano V, Malvehy J, Berrocal A, et al
     Treatment patterns of adjuvant interferon-alpha2b for high-risk melanoma: a retrospective study of the Grupo Espanol Multidisciplinar de Melanoma - Prima study.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     February 2016
217. PATEL BG, Ahmed KA, Johnstone PA, Yu HM, et al
     Initial experience with combined BRAF and MEK inhibition with stereotactic radiosurgery for BRAF mutant melanoma brain metastases.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
218. SINGH P, Kim HJ, Schwartz RA
     Superficial spreading melanoma: an analysis of 97 702 cases using the SEER database.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
219. TAS F, Bilgin E, Erturk K, Duranyildiz D, et al
     Clinical significance of serum claudin-1 levels in melanoma patients.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
220. VOIT CA, Oude Ophuis CM, Ulrich J, van Akkooi AC, et al
     Ultrasound of the sentinel node in melanoma patients: echo-free island is a discriminatory morphologic feature for node positivity.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
221. MORIARTY WF, Kim E, Gerber SA, Hammers H, et al
     Neuropilin-2 promotes melanoma growth and progression in vivo.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
222. KOTTSCHADE LA, McWilliams RR, Markovic SN, Block MS, et al
     The use of pembrolizumab for the treatment of metastatic uveal melanoma.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
223. IMREDI E, Toth B, Doma V, Barbai T, et al
     Aquaporin 1 protein expression is associated with BRAF V600 mutation and adverse prognosis in cutaneous melanoma.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
224. KILIAN MM, Herwig MC, Holz FG, Tuting T, et al
     Overexpression of hepatocyte growth factor and an oncogenic CDK4 variant in mice alters corneal stroma morphology but does not lead to spontaneous ocular melanoma.
     Melanoma Res. 2016;26:89-91.
     PubMed     Text format    
     
     
     
225. SLOOT S, Zager JS, Kudchadkar RR, Messina JL, et al
     BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma: a potential neoadjuvant strategy.
     Melanoma Res. 2016;26:83-7.
     PubMed     Text format     Abstract available
     
     
     
226. SALDANHA G, Potter L, Lee YS, Watson S, et al
     MicroRNA-21 expression and its pathogenetic significance in cutaneous melanoma.
     Melanoma Res. 2016;26:21-8.
     PubMed     Text format     Abstract available
     
     
     
227. PISCIOLI F, Pusiol T, Roncati L
     Diagnostic approach to melanocytic lesion of unknown malignant potential.
     Melanoma Res. 2016;26:91-2.
     PubMed     Text format    
     
     
     January 2016
228. TODO Y, Okamoto K, Suzuki Y, Minobe S, et al
     Radicality of initial surgery for primary malignant melanoma of the vagina.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
229. CHIRIBOGA L, Meehan S, Osman I, Glick M, et al
     Endothelin-1 in the tumor microenvironment correlates with melanoma invasion.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
230. KONG BY, Micklethwaite KP, Swaminathan S, Kefford RF, et al
     Autoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanoma.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
231. SHOUSHTARI AN, Ong LT, Schoder H, Singh-Kandah S, et al
     A phase 2 trial of everolimus and pasireotide long-acting release in patients with metastatic uveal melanoma.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
232. GLAZER ES, Bartels PH, Lian F, Kha ST, et al
     Quantitative histopathology identifies patients with thin melanomas who are at risk for metastases.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
233. MUSTAPHA N, Mokdad-Bzeouich I, Maatouk M, Ghedira K, et al
     Antitumoral, antioxidant, and antimelanogenesis potencies of Hawthorn, a potential natural agent in the treatment of melanoma.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     December 2015
234. DE LIMA VAZQUEZ V, Vicente AL, Carloni A, Berardinelli G, et al
     Molecular profiling, including TERT promoter mutations, of acral lentiginous melanomas.
     Melanoma Res. 2015.
     PubMed     Text format     Abstract available
     
     
     
235. SEIFERT H, Fisher R, Martin-Liberal J, Edmonds K, et al
     Prognostic markers and tumour growth kinetics in melanoma patients progressing on vemurafenib.
     Melanoma Res. 2015.
     PubMed     Text format     Abstract available
     
     
     
236. SHEPPARD HM, Feisst V, Chen J, Print C, et al
     AHNAK is downregulated in melanoma, predicts poor outcome, and may be required for the expression of functional cadherin-1.
     Melanoma Res. 2015.
     PubMed     Text format     Abstract available
     
     
     
237. KOROKNAI V, Ecsedi S, Vizkeleti L, Kiss T, et al
     Genomic profiling of invasive melanoma cell lines by array comparative genomic hybridization.
     Melanoma Res. 2015.
     PubMed     Text format     Abstract available
     
     
     
238. SCHREUER M, Meersseman G, van Den Herrewegen S, Jansen Y, et al
     Applications for quantitative measurement of BRAF V600 mutant cell-free tumor DNA in the plasma of patients with metastatic melanoma.
     Melanoma Res. 2015.
     PubMed     Text format     Abstract available
     
     
     
239. JACOBSOONE-ULRICH A, Jamme P, Alkeraye S, Dzwiniel V, et al
     Ipilimumab in anti-PD1 refractory metastatic melanoma: a report of eight cases.
     Melanoma Res. 2015.
     PubMed     Text format     Abstract available
     
     
     
240. SONG H, Jing G, Wang L, Guo W, et al
     Periodic acid-Schiff-positive loops and networks as a prognostic factor in oral mucosal melanoma.
     Melanoma Res. 2015.
     PubMed     Text format     Abstract available
     
     
     
241. JANSEN YJ, Janssens P, Hoorens A, Schreuer MS, et al
     Granulomatous nephritis and dermatitis in a patient with BRAF V600E mutant metastatic melanoma treated with dabrafenib and trametinib.
     Melanoma Res. 2015;25:550-554.
     PubMed     Text format     Abstract available
     
     
     
242. SEVIM DG, Kiratli H
     Serum adiponectin, insulin resistance, and uveal melanoma: clinicopathological correlations.
     Melanoma Res. 2015.
     PubMed     Text format     Abstract available
     
     
     
243. OLSEN CM, Lane SW, Green AC
     Increased risk of melanoma in patients with chronic lymphocytic leukaemia: systematic review and meta-analysis of cohort studies.
     Melanoma Res. 2015.
     PubMed     Text format     Abstract available
     
     
     November 2015
244. CAMPAGNE C, Reyes-Gomez E, Loiodice S, Gadin S, et al
     Haplosufficiency of PAX3 for melanoma development in Tyr: NRASQ61K; Cdkn2a-/- mice allows identification and sorting of melanoma cells using a Pax3GFP reporter allele.
     Melanoma Res. 2015.
     PubMed     Text format     Abstract available
     
     
     October 2015
245. LI P, Liu J
     Diagnostic value of MRI and computed tomography in anorectal malignant melanoma.
     Melanoma Res. 2015.
     PubMed     Text format     Abstract available
     
     
     
246. EIBL-LINDNER K, Furweger C, Nentwich M, Foerster P, et al
     Robotic radiosurgery for the treatment of medium and large uveal melanoma.
     Melanoma Res. 2015.
     PubMed     Text format     Abstract available
     
     
     
247. BANERJEE M, Lao CD, Wancata LM, Muenz DG, et al
     Implications of age and conditional survival estimates for patients with melanoma.
     Melanoma Res. 2015.
     PubMed     Text format     Abstract available
     
     
     
248. IBRAHIM AM, Vargas CR, Koolen PG, Chuang DJ, et al
     Readability of online patient resources for melanoma.
     Melanoma Res. 2015.
     PubMed     Text format     Abstract available
     
     
     
249. O'CONNELL EP, O'Leary DP, Fogarty K, Khan ZJ, et al
     Predictors and patterns of melanoma recurrence following a negative sentinel lymph node biopsy.
     Melanoma Res. 2015.
     PubMed     Text format     Abstract available
     
     
     
250. CINTOLO JA, Datta J, Xu S, Gupta M, et al
     Type I-polarized BRAF-pulsed dendritic cells induce antigen-specific CD8+ T cells that impact BRAF-mutant murine melanoma.
     Melanoma Res. 2015.
     PubMed     Text format     Abstract available
     
     
     September 2015
251. SHIMIZU A, Kaira K, Yasuda M, Asao T, et al
     Decreased expression of class III beta-tubulin is associated with unfavourable prognosis in patients with malignant melanoma.
     Melanoma Res. 2015.
     PubMed     Text format     Abstract available
     
     
     
252. RUBEGNI P, Feci L, Nami N, Burroni M, et al
     Computer-assisted melanoma diagnosis: a new integrated system.
     Melanoma Res. 2015.
     PubMed     Text format     Abstract available
     
     
     
253. COUPS EJ, Manne SL, Stapleton JL, Tatum KL, et al
     Skin self-examination behaviors among individuals diagnosed with melanoma.
     Melanoma Res. 2015.
     PubMed     Text format     Abstract available
     
     
     
254. ROUX J, Pages C, Malouf D, Basset Seguin N, et al
     BRAF inhibitor rechallenge in patients with advanced BRAF V600-mutant melanoma.
     Melanoma Res. 2015.
     PubMed     Text format     Abstract available
     
     
     
255. OLIVER DE, Patel KR, Switchenko J, Parker D, et al
     Roles of adjuvant and salvage radiotherapy for desmoplastic melanoma.
     Melanoma Res. 2015.
     PubMed     Text format     Abstract available
     
     
     
256. KELLER AK, Uter W, Pfahlberg AB, Radespiel-Troger M, et al
     Replacing surrogate measures by direct quantification of ultraviolet radiation exposure in registry-based analyses of seasonality of melanoma diagnoses.
     Melanoma Res. 2015.
     PubMed     Text format     Abstract available
     
     
     
257. BERTOLLI E, Macedo MP, Pinto CA, Damascena AS, et al
     Metastatic area ratio can help predict nonsentinel node positivity in melanoma patients.
     Melanoma Res. 2015.
     PubMed     Text format     Abstract available
     
     
     
258. TRIOZZI PL, Aldrich W, Crabb JW, Singh AD, et al
     Spontaneous cellular and humoral tumor antigen responses in patients with uveal melanoma.
     Melanoma Res. 2015.
     PubMed     Text format     Abstract available
     
     
     
259. DUMMER R, Schadendorf D, Ascierto PA, Larkin J, et al
     Integrating first-line treatment options into clinical practice: what's new in advanced melanoma?
     Melanoma Res. 2015.
     PubMed     Text format     Abstract available
     
     
     
260. GONZALEZ-CAO M, Mayo-de-Las-Casas C, Molina-Vila MA, De Mattos-Arruda L, et al
     BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors.
     Melanoma Res. 2015.
     PubMed     Text format     Abstract available
     
     
     
261. THIERAUF J, Veit JA, Affolter A, Bergmann C, et al
     Identification and clinical relevance of PD-L1 expression in primary mucosal malignant melanoma of the head and neck.
     Melanoma Res. 2015.
     PubMed     Text format     Abstract available
     
     
     
262. LATIMER NR, Amonkar MM, Stapelkamp C, Sun P, et al
     Adjusting for confounding effects of treatment switching in a randomized phase II study of dabrafenib plus trametinib in BRAF V600+ metastatic melanoma.
     Melanoma Res. 2015.
     PubMed     Text format     Abstract available
     
     
     August 2015
263. NAFFOUJE S, Naffouje R, Bhagwandin S, Salti GI, et al
     Microphthalmia transcription factor in malignant melanoma predicts occult sentinel lymph node metastases and survival.
     Melanoma Res. 2015.
     PubMed     Text format     Abstract available
     
     
     
264. FILITIS DC, Rauh J, Mahalingam M
     The HGF-cMET signaling pathway in conferring stromal-induced BRAF-inhibitor resistance in melanoma.
     Melanoma Res. 2015.
     PubMed     Text format     Abstract available
     
     
     
265. SIISKONEN H, Poukka M, Bykachev A, Tyynela-Korhonen K, et al
     Low numbers of tryptase+ and chymase+ mast cells associated with reduced survival and advanced tumor stage in melanoma.
     Melanoma Res. 2015.
     PubMed     Text format     Abstract available
     
     
     
266. GAMBICHLER T, Scheitz R, Hoxtermann S
     Serum anti-BPAG1 autoantibody level is not a useful biomarker for cutaneous melanoma.
     Melanoma Res. 2015.
     PubMed     Text format    
     
     
     
267. SALGADO CM, Basu D, Nikiforova M, Hamilton RL, et al
     Amplification of mutated NRAS leading to congenital melanoma in neurocutaneous melanocytosis.
     Melanoma Res. 2015.
     PubMed     Text format     Abstract available
     
     
     
268. RUINI C, Manfredini M, Pellacani G, Mandel VD, et al
     Confocal microscopy characterization of BRAFV600E mutated melanomas.
     Melanoma Res. 2015;25:367-371.
     PubMed     Text format     Abstract available
     
     
     July 2015
269. MORENO-RAMIREZ D, Ojeda-Vila T, Rios-Martin JJ, Nieto-Garcia A, et al
     Association between tumor size and Breslow's thickness in malignant melanoma: a cross-sectional, multicenter study.
     Melanoma Res. 2015.
     PubMed     Text format     Abstract available
     
     
     
270. SHIMIZU A, Kaira K, Kato M, Yasuda M, et al
     Prognostic significance of L-type amino acid transporter 1 (LAT1) expression in cutaneous melanoma.
     Melanoma Res. 2015.
     PubMed     Text format     Abstract available
     
     
     
271. NOGUCHI S, Mori T, Nakagawa T, Itamoto K, et al
     DNA methylation contributes toward silencing of antioncogenic microRNA-203 in human and canine melanoma cells.
     Melanoma Res. 2015.
     PubMed     Text format     Abstract available
     
     
     
272. S AHMAD S, Qian W, Ellis S, Mason E, et al
     Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients.
     Melanoma Res. 2015.
     PubMed     Text format     Abstract available
     
     
     
273. BURGSTALLER-MUEHLBACHER S, Marko M, Muller C, Wendt J, et al
     Novel CDKN2A mutations in Austrian melanoma patients.
     Melanoma Res. 2015.
     PubMed     Text format     Abstract available
     
     
     
274. JAKUB JW, Grotz TE, Jordan P, Hunter E, et al
     A pilot study of chromosomal aberrations and epigenetic changes in peripheral blood samples to identify patients with melanoma.
     Melanoma Res. 2015.
     PubMed     Text format     Abstract available
     
     
     
275. DONINA S, Strele I, Proboka G, Auzins J, et al
     Adapted ECHO-7 virus Rigvir immunotherapy (oncolytic virotherapy) prolongs survival in melanoma patients after surgical excision of the tumour in a retrospective study.
     Melanoma Res. 2015.
     PubMed     Text format     Abstract available
     
     
     
276. SAROJINI S, Pecora A, Milinovikj N, Barbiere J, et al
     A combination of high dose rate (10X FFF/2400 MU/min/10 MV X-rays) and total low dose (0.5 Gy) induces a higher rate of apoptosis in melanoma cells in vitro and superior preservation of normal melanocytes.
     Melanoma Res. 2015.
     PubMed     Text format     Abstract available
     
     
     
277. LEJEUNE FJ
     The conquest of melanoma by immunotherapy.
     Melanoma Res. 2015.
     PubMed     Text format    
     
     
     June 2015
278. DEROOSE JP, Grunhagen DJ, Eggermont AM, Verhoef C, et al
     Repeated isolated limb perfusion in melanoma patients with recurrent in-transit metastases.
     Melanoma Res. 2015.
     PubMed     Text format     Abstract available
     
     
     
279. GOVERNA M, Caprarella E, Dalla Pozza E, Vigato E, et al
     Association of CDK4 germline and BRAF somatic mutations in a patient with multiple primary melanomas and BRAF inhibitor resistance.
     Melanoma Res. 2015.
     PubMed     Text format     Abstract available
     
     
     
280. VAN BEEK JG, Koopmans AE, Vaarwater J, Verdijk RM, et al
     Metastatic disease in uveal melanoma: importance of a genetic profile?
     Melanoma Res. 2015.
     PubMed     Text format     Abstract available
     
     
     
281. TOLK H, Satzger I, Mohr P, Zimmer L, et al
     Complete remission of metastatic melanoma upon BRAF inhibitor treatment - what happens after discontinuation?
     Melanoma Res. 2015.
     PubMed     Text format     Abstract available
     
     
     
282. GORDON D, Gillgren P, Eloranta S, Olsson H, et al
     Time trends in incidence of cutaneous melanoma by detailed anatomical location and patterns of ultraviolet radiation exposure: a retrospective population-based study.
     Melanoma Res. 2015.
     PubMed     Text format     Abstract available
     
     
     
283. JOSHUA AM, Monzon JG, Mihalcioiu C, Hogg D, et al
     A phase 2 study of tremelimumab in patients with advanced uveal melanoma.
     Melanoma Res. 2015.
     PubMed     Text format     Abstract available
     
     
     
284. CHEVOLET I, Schreuer M, Speeckaert R, Neyns B, et al
     Systemic immune changes associated with adjuvant interferon-alpha2b-therapy in stage III melanoma patients: failure at the effector phase?
     Melanoma Res. 2015.
     PubMed     Text format     Abstract available
     
     
     
285. YOUSAF N, Davidson M, Goode E, Thomas C, et al
     The cost of ipilimumab toxicity: a single-centre analysis.
     Melanoma Res. 2015;25:259-64.
     PubMed     Text format     Abstract available
     
     
     May 2015
286. MINICHSDORFER C, Wasinger C, Sieczkowski E, Atil B, et al
     Tocilizumab unmasks a stage-dependent interleukin-6 component in statin-induced apoptosis of metastatic melanoma cells.
     Melanoma Res. 2015.
     PubMed     Text format     Abstract available
     
     
     
287. NARDIN C, Puzenat E, Pretet JL, Algros MP, et al
     BRAF mutation screening in melanoma: is sentinel lymph node reliable?
     Melanoma Res. 2015.
     PubMed     Text format     Abstract available
     
     
     
288. ROLAND CL, Ross MI, Hall CS, Laubacher B, et al
     Detection of circulating melanoma cells in the blood of melanoma patients: a preliminary study.
     Melanoma Res. 2015.
     PubMed     Text format     Abstract available
     
     
     
289. CHALOPIN B, Florenceau L, Fradin D, Labarriere N, et al
     A lineage-specific methylation pattern controls the transcription of the polycistronic mRNA coding MELOE melanoma antigens.
     Melanoma Res. 2015.
     PubMed     Text format     Abstract available
     
     
     February 2015
290. KALTOFT B, Hainau B, Lock-Andersen J
     Melanocytic tumour with unknown malignant potential--a Danish study of 67 patients.
     Melanoma Res. 2015;25:64-7.
     PubMed     Text format     Abstract available
     
     
     October 2014
291. RILEY PA
     Failure of fidelity of vertical transmission of epigenetic patterning as the basis of cancer.
     Melanoma Res. 2014;24:424-7.
     PubMed     Text format    
     
     
     
292. ROBERT C, Thomas M, Mateus C
     MAP-kinase pathway up or down? Just look at the skin of your patients!
     Melanoma Res. 2014;24:421-3.
     PubMed     Text format    
     
     
     
293. VOIT CA, van Akkooi AC, Eggermont AM, Tuttenberg A, et al
     Ultrasound diagnosis of an atypical axillary lesion.
     Melanoma Res. 2014;24:517-21.
     PubMed     Text format     Abstract available
     
     
     
294. MCCORMACK CJ, Conyers RK, Scolyer RA, Kirkwood J, et al
     Atypical Spitzoid neoplasms: a review of potential markers of biological behavior including sentinel node biopsy.
     Melanoma Res. 2014;24:437-47.
     PubMed     Text format     Abstract available
     
     
     
295. FORSCHNER A, Zips D, Schraml C, Rocken M, et al
     Radiation recall dermatitis and radiation pneumonitis during treatment with vemurafenib.
     Melanoma Res. 2014;24:512-6.
     PubMed     Text format     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: